繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

Cue Biopharma Q2 Net Loss Narrows, Revenue Rises

2024-08-20 05:23

05:23 PM EDT, 08/19/2024 (MT Newswires) -- Cue Biopharma (CUE) reported a Q2 net loss late Monday of $0.20 per diluted share, narrowing from a loss of $0.29 a year earlier.

Four analysts polled by Capital IQ expected a loss of $0.27.

Revenue for the quarter ended June 30 was $2.7 million, up from $1.4 million a year earlier. Four analysts surveyed by Capital IQ expected $1.3 million.

Cue Biopharma said its cash and cash equivalents as of June 30 were $30 million down from $48.5 million a year earlier.

Current cash, cash equivalents and marketable securities will fund operations through Q2 2025, according to the company.

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。